CLNN — Q2 2026 Financial Report Analysis

Overview

Clene is a clinical-stage drug developer: it has no approved medicine and earns almost nothing from sales. Its whole value rests on CNM-Au8, an oral suspension of gold nanocrystals it is testing in ALS (amyotrophic lateral sclerosis, also called Lou Gehrig's disease) and multiple sclerosis. For a company like this the quarter's real questions are how much cash is left, how fast it is being spent, and whether the drug is getting closer to approval.

Q2 2026 answered all three. The net loss nearly doubled to $13.4 million ($1.08 per share), but that is mostly an accounting effect. The cost of running the business fell: the operating loss narrowed to $5.3 million from $5.9 million. Cash rose to $9.7 million thanks to two stock sales, and management now plans to file for FDA approval of CNM-Au8 in ALS in early Q4 2026 under the accelerated approval pathway. It also says its cash only lasts until late Q4 2026.

At a glance

• $9.7 million in cash on June 30, against $7.1 million burned by operations in the first half. The 10-Q itself says there is "substantial doubt" the company can keep operating for another year without new money.
• $7.5 million of the $13.4 million quarterly loss came from revaluing warrants and convertible-note features as the share price moved. No cash left the company for these; strip them out and the loss shrank year on year.
• NDA planned for early Q4 2026. An NDA (new drug application) is the formal request for permission to sell a drug. FDA minutes from May say the data "may be capable of supporting" a filing, but the key supporting analyses are post hoc, meaning they were run after the trials ended.

Results at a glance

All figures in US$ millions except per-share amounts. Three months ended June 30.

Revenue comes from zinc-silver and gold dietary supplements, sold mainly to 4Life Research, a related party that is also a stockholder and lender. At $90,000 a quarter it is immaterial, so a profit margin would mean nothing here. On April 30, 2026 Clene ended 4Life's exclusive right to buy these products, because 4Life missed its minimum sales commitment for two years running.

Takeaway: The business itself spent less this quarter, and the headline loss is mostly paper. But Clene had about $7.7 million of cash it could actually use (after the $2.0 million minimum its lenders require), plus $4.0 million raised in September. That pays for roughly a few months of work. The company has to file its NDA and find more money at about the same time, and how the market receives the filing will largely decide the price of that money.

Where the money went

R&D (research and development) was flat for the quarter but down 24% for the half year, to $3.8 million. The mix inside it shifted towards getting the FDA filing done:

• ALS clinical spending halved, to $0.71 million from $1.47 million. The 10-Q says this reflects lower costs for the two expanded access programs with Massachusetts General Hospital, the NIH-sponsored compassionate-use program (ACT-EAP), and less planning work on the RESTORE-ALS Phase 3 trial. An expanded access program supplies an unapproved drug to patients outside a trial.
• MS spending fell to $37,000 from $164,000 now that the REPAIR-MS trial has finished.
• Regulatory spending nearly tripled, to $0.37 million from $0.13 million, driven by FDA discussions and NDA preparation.
• Manufacturing rose to $0.52 million from $0.19 million because Clene used gold bought at higher commodity prices.

Grants are a large hidden offset. Clene subtracts grant reimbursements, mostly for the NIH-sponsored ACT-EAP, directly from its R&D expense. In the first half that offset was $5.9 million, so R&D before reimbursement was about $9.7 million. Q1 alone carried $4.05 million of offsets and a one-time credit when Clene's supplier reprocessed gold lots after the gold price rose. Together they cut Q1's reported R&D to about $0.33 million. Comparing the two quarters, Q2's R&D did not jump tenfold. Q1 was unusually low.

G&A (general and administrative costs, the overhead of running a public company) fell 19%. Lower legal fees, lower audit and accounting fees and lower stock-based pay drove the decline, along with what the 10-Q calls "cost-saving initiatives", which included cutting pay and eliminating some positions.

What the headline numbers hide

• The net loss is mostly non-cash. Clene has issued warrants (rights to buy shares at a set price) and convertible notes (loans that can turn into shares). Accounting rules require the company to re-price both at fair value every quarter, and when its stock rises these liabilities grow and the increase is booked as a loss. In Q2 those charges were $4.13 million on warrants and $3.33 million on note features. For the half year, net loss was $21.5 million but operating cash outflow was $7.1 million. The gap includes a $4.6 million "loss on initial issuance of equity" from January's offering, recorded because the shares and warrants sold were worth more than the cash received.
• The cash line looks better than it is. The 2024 senior secured convertible notes require at least $2.0 million in unrestricted cash at all times or the full balance comes due. So only about $7.7 million of the $9.7 million was usable. At the first half's average of about $1.2 million a month of operating cash burn, that is roughly six months, which matches management's own "late fourth quarter 2026" runway estimate. The $4.0 million raised in September adds about three months at that pace, unless NDA work makes spending rise. Part of the liabilities that make the balance sheet look so weak ($16.1 million of warrant liabilities) would never be paid in cash. The debt is real.
• Debt was pushed out, not reduced. In May, Clene extended both secured convertible note facilities ($10.0 million and $1.5 million principal, 12% interest) to August 2027 and removed all principal and interest payments before then. That eases near-term cash needs, but it creates a wall: the 10-Q lists $21.2 million of note principal and interest due beyond the next 12 months. Stockholders' equity is negative $24.8 million, meaning liabilities exceed assets.
• Dilution is heavy and getting cheaper for new investors. The weighted-average share count rose 30% year on year to 12.4 million. In 2026 Clene sold shares in January ($6.0 million with warrants), May (1.0 million shares at $7.00) and September (1.22 million shares at $3.28, mostly to existing holders including directors and officers). The September price was less than half May's. Warrants from January cover a further 3.7 million shares at $6.00. Their terms raise the exercise price if they are exercised before FDA milestones, which encourages holders to exercise early and gives Clene a possible source of cash.
• Loss per share understates the per-share hit. The 38% rise in loss per share is smaller than the 81% rise in net loss only because the losses were spread over more shares.

The pipeline: what the FDA has and hasn't said

ALS. Accelerated approval lets the FDA approve a drug for a serious disease based on a "surrogate" marker that is reasonably likely to predict real benefit, provided the company later confirms that benefit in a larger trial. Clene's surrogate is NfL (neurofilament light chain), a blood marker that rises when nerve cells are damaged. At a March 2026 meeting, the FDA acknowledged that NfL has established prognostic value in ALS and could potentially serve as such a marker. Its May minutes stated that Clene's data "may be capable of supporting the submission and review of an NDA." The FDA also asked Clene to show that the size of the NfL change is reasonably likely to predict clinical benefit.

Clene's answer, announced in August, is new analyses of its two Phase 2 trials (HEALEY and RESCUE-ALS). Treated patients whose NfL declined or held steady lived significantly longer than randomized controls, and did better on combined measures of survival, daily function and breathing capacity. The 10-Q itself calls these "post hoc exploratory findings": they look at a subgroup chosen after the fact rather than at a pre-specified trial goal. Regulators usually give such evidence less weight, and the FDA has only said the data may support a filing, not that it supports approval. If approved, a Phase 3 trial, RESTORE-ALS, would serve as the confirmatory study. It is planned to start in Q2 2027.

MS. After a 2025 end-of-Phase-2 meeting, the FDA said it was open to endpoints such as cognition. Clene has not committed money to a Phase 3 study and says licensing the MS indication becomes easier once CNM-Au8 is approved for something else.

Outlook

Management's guidance is short: NDA submission in early Q4 2026, cash runway to late Q4 2026, and RESTORE-ALS starting in Q2 2027. As of October 14, 2026 Clene had not filed an 8-K announcing the NDA submission. The September stock sale was explicitly to fund "continued regulatory dialogue and preparation of regulatory filings and a new drug application", which suggests the filing was still being assembled then.

Our read: the next two milestones decide almost everything. The first is whether the NDA goes in on time. The second is whether the FDA accepts it for review, a decision normally made within about 60 days of submission. Accepting the file for review is not the same as approving it. Even with good news, Clene must raise more money around year-end, and with total liabilities of $47.8 million against $23.0 million of assets, that is likely to mean more dilution or more convertible debt. A delay or a refusal to file would leave a company with weeks of cash and an August 2027 debt deadline. In the Q3 10-Q, due around mid-November, watch three things: the cash balance against the $2.0 million covenant, any change to the runway statement, and whether the NDA submission is confirmed.